Achieve Life Sciences Statistics
Share Statistics
Achieve Life Sciences has 34.39M shares outstanding. The number of shares has increased by 62.25% in one year.
| Shares Outstanding | 34.39M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 27.60M |
| Failed to Deliver (FTD) Shares | 5.36K |
| FTD / Avg. Volume | 4.74% |
Short Selling Information
The latest short interest is 3.32M, so 9.65% of the outstanding shares have been sold short.
| Short Interest | 3.32M |
| Short % of Shares Out | 9.65% |
| Short % of Float | 12.03% |
| Short Ratio (days to cover) | 33.44 |
Valuation Ratios
The PE ratio is -2.74 and the forward PE ratio is -4.04.
| PE Ratio | -2.74 |
| Forward PE | -4.04 |
| PS Ratio | 0 |
| Forward PS | 8.6 |
| PB Ratio | -56.41 |
| P/FCF Ratio | -3.33 |
| PEG Ratio | n/a |
Enterprise Valuation
Achieve Life Sciences Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.82, with a Debt / Equity ratio of -11.51.
| Current Ratio | 0.82 |
| Quick Ratio | 0.82 |
| Debt / Equity | -11.51 |
| Total Debt / Capitalization | 109.52 |
| Cash Flow / Debt | -1.47 |
| Interest Coverage | -9.55 |
Financial Efficiency
Return on equity (ROE) is 20.59% and return on capital (ROIC) is -178.3%.
| Return on Equity (ROE) | 20.59% |
| Return on Assets (ROA) | -1.54% |
| Return on Capital (ROIC) | -178.3% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.36M |
| Employee Count | 22 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 28.62% in the last 52 weeks. The beta is 1.58, so Achieve Life Sciences 's price volatility has been higher than the market average.
| Beta | 1.58 |
| 52-Week Price Change | 28.62% |
| 50-Day Moving Average | 4.66 |
| 200-Day Moving Average | 4.67 |
| Relative Strength Index (RSI) | 35.07 |
| Average Volume (20 Days) | 112.96K |
Income Statement
In the last 12 months, Achieve Life Sciences had revenue of $0 and earned -$29.82M in profits. Earnings per share was $-1.5.
| Revenue | 0 |
| Gross Profit | -228.00K |
| Operating Income | -27.25M |
| Net Income | -29.82M |
| EBITDA | -26.73M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.5 |
Balance Sheet
The company has $15.55M in cash and $16.73M in debt, giving a net cash position of -$1.19M.
| Cash & Cash Equivalents | 15.55M |
| Total Debt | 16.73M |
| Net Cash | -1.19M |
| Retained Earnings | -165.75M |
| Total Assets | 47.92M |
| Working Capital | 38.81M |
Cash Flow
In the last 12 months, operating cash flow was -$24.48M and capital expenditures -$21.00K, giving a free cash flow of -$24.50M.
| Operating Cash Flow | -24.48M |
| Capital Expenditures | -21.00K |
| Free Cash Flow | -24.50M |
| FCF Per Share | -1.24 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ACHV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -36.67% |
| FCF Yield | -17.42% |
Analyst Forecast
The average price target for ACHV is $12, which is 193.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $12 |
| Price Target Difference | 193.4% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Jul 31, 2020. It was a backward split with a ratio of 1:20.
| Last Split Date | Jul 31, 2020 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -1.59 |
| Piotroski F-Score | 3 |